Given oil's importance in a growing global economy, natural gas and oil companies are likely to continue to experience steady demand for their services/products, and a provider worth a review is Cimarex Energy.
Cimarex Energy (NYSE: XEC) is an independent oil and gas exploration and production company.
In general, analysts see 2-5% production growth in F2008, including impressive drilling activity in the Permian Basin, Mid-Continent Granite Wash, and Gulf Coast Yegua/Cook Mountain regions. The company has proved reserves of more than 1.4 trillion cubic feet of natural gas equivalent.
Meanwhile, given high service costs, XEC is expected to be more selective regarding projects, favoring those projects that meet reservoir size requirements and that do not exceed project cost limits. The Reuters F2008/F2009 EPS consensus estimates for XEC are $4.89/$4.71
The risks? A substantial, sustained decline in oil / natural gas prices would hurt XEC's results. Production underperformance or severe weather also would hurt the company's results.
The First Call mean rating for XEC is: Hold. [6 firms.] Mean 2008 target: $58. [high: $68, low: $50.]
Stock Analysis: Cimarex Energy is a moderate-risk stock not suitable for low-risk investors. Investors with an investment horizon longer than 2 years should be rewarded from XEC's shares. Note: More-cautious investors may consider waiting until XEC pulls-back to $51, but keep in mind that XEC may not retreat to that level. Sell / Stop Loss if you were to purchase shares in this company: $36.
Disclosure: Lazzaro has no positions in stocks. In addition to private real estate holdings, he owns corporate and municipal bonds, and cash certificates of deposit.
Last updated: February 10, 2012: 09:08 AM
Hot Stocks
DailyFinance Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
Benzinga Headlines
- Chesapeake Gently Lets Go of Gas
- How to Profit off Addicts
- The Pepsi Challenge for 8,700 People is to Find a New Job
- How to Profit From Surging Chinese Prices
- Credit Suisse is the Latest Swiss Bank to Disappoint
TheFlyOnTheWall.com Headlines
- Omnicom management to meet with JPMorgan
- NetApp volatility elevated into Q3 and growth outlook
- EMRISE and lender amend loan terms; allows dicount payoff up to 30%
- Alexion target raised to $90 from $76 at ThinkEquity
- Actuant management to meet with JPMorgan
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
WalletPop Headlines
- Walmart's New Health Food Push: Is It Too Hard to Swallow?
- Newlyweds, Don't Let the IRS Spoil Your Honeymoon
- Bonds Are a 'Safe' Investment: A Big Lie Gets Even Bigger
- Why Groupon Will Never Be Great Again
- Why Used Car Bargains Are Getting Harder to Find
My Portfolios
Track your stocks here!
Find out why more people track their portfolios on AOL Money & Finance then anywhere else.
BloggingStocks Partners
More from AOL Money & Finance
- Business News
- Stock Screener
- Stock Quotes
- Stock Charts
- Banking
- Identity Theft
- DJIA
- Debt Management
- Loans
- Auto Loan
- Mortgages
- Taxes
- Retirement
- Insurance
- Small Business
- Earnings
- Tech News
- Tax Forms
- Tax Deductions
- Tax Credit
- Tax Audit
- Tax Advice
- Stock Ticker
- Stock Brokers
- Resume Builder
- Pig Flu
- Online Tax Filing
- Madoff
- Investing For Retirement
- Income Tax
- Historical Stock Prices
- GOOG
- ETF Investing
- Deals
- DailyFinance
- Crude Oil Prices
- Credit Score Calculator
- Common Tax Filing Mistakes
- AMT
BioHealth Investor Headlines
- Can Human Genome Really Double Its Stock Price? (HGSI)
- Alimera Implosion Analysis, What Is Next (ALIM, PSDV)
- Implosion Analysis For Targacept… What Lies Ahead? (TRGT, AZN)
- Rare Analyst Calls With Huge Upside in Vical and VIVUS (VICL, VVUS, BMY)
- Top Biotechs With Upside Ahead of Earnings (GILD, AMLN, ARIA, INCY, JAZZ, DNDN, HGSI, ILMN, AMGN, CELG, BIIB, BMRN, LIFE, REGN, AMLN, CBST, ONXX, THRX, VPHM)
The Money Man Behind Rick Santorum: Who Is Foster S. Friess?
Savings Experiment: Snow Removal

